Ojaswi Ghadge, Anubha Khale, Ajit Wankhede
firstname.lastname@example.org , email@example.com
Ojaswi Ghadge1*, Anubha Khale2, Ajit Wankhede3
1Assistant Professor, H. K. College of Pharmacy, Oshiwara, Jogeshwari (W), Mumbai- 400102
2Principal, H. K. College of Pharmacy, Oshiwara, Jogeshwari (W), Mumbai- 400102
3 Assistant Professor, Sandip Foundation‘s Sandip Institute of Pharmaceutical Sciences, Nasik- 400213
Volume - 7,
Issue - 8,
Year - 2014
Antibody drug conjugates (ADCs) is an emerging class of Biotherapeutics which represents a unique treatment strategy in the field of Oncology. The majority of anticancer agents developed to date have substantial side effect profiles and a narrow therapeutic index. Antibody-drug conjugates (ADCs) combine the specificity of monoclonal antibodies (mAbs) with the potency of cytotoxic molecules, thus takes advantage of the best characteristics of both components. The emphasis of this article is to provide an overview of the design of ADCs which are intended to target and kill cancerous cells, their characteristics, challenges in the formulation of ADCs, cytotoxic agents used in the process, chemical linkers, their types and the type of monoclonal antibody (mAb) used to make up the components of the ADC. Also various analytical methods required for characterization and analysis of ADCs are also briefed.
Cite this article:
Ojaswi Ghadge, Anubha Khale, Ajit Wankhede. Antibody Drug Conjugation: Future of Cancer Care. Research J. Pharm. and Tech. 7(8): August 2014 Page 931-937.